Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

Bayer’s multimillion dollar birth control pill, Yaz, will go head-to-head with generic competition with the introduction of Teva Pharmaceutical Industries’ Gianvi. Teva was awarded a 180-day marketing exclusivity period for Gianvi by the Food and Drug Administration after being the first company to file an Abbreviated New Drug Application (ANDA). Bayer isn’t taking the news lightly. The company says it plans to sue Teva for prematurely launching the new “girl” on the block, which Bayer says they are not legally permitted to do until July 2011.

Read the rest of this entry »